Elevance Health (0HG8) Share Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0HG8 Analyst Ratings

Moderate Buy

9 Buy

5 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Elevance

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0HG8 Stock 12 Month Forecast

Average Price Target

$477.38

▲(20.50% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $477.38 with a high forecast of $523.00 and a low forecast of $406.00. The average price target represents a 20.50% change from the last price of $396.17.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"288":"$288","347":"$347","406":"$406","465":"$465","524":"$524"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":523,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$523.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":477.38461538461536,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$477.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":406,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$406.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[288,347,406,465,524],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,381.87,392.72615384615386,403.5823076923077,414.4384615384615,425.2946153846154,436.15076923076924,447.0069230769231,457.86307692307696,468.71923076923076,479.5753846153846,490.4315384615385,501.2876923076923,512.1438461538462,{"y":523,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,381.87,389.2172781065089,396.56455621301774,403.91183431952663,411.2591124260355,418.60639053254437,425.95366863905326,433.3009467455621,440.648224852071,447.9955029585799,455.34278106508873,462.6900591715976,470.03733727810646,{"y":477.38461538461536,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,381.87,383.72615384615386,385.5823076923077,387.4384615384615,389.2946153846154,391.15076923076924,393.0069230769231,394.8630769230769,396.71923076923076,398.5753846153846,400.4315384615385,402.2876923076923,404.14384615384614,{"y":406,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":324.611,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":309.206,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.553,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.278,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":337.106,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":289.471,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":369.716,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":398.176,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408.445,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":375.75,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":399.547,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":381.87,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$523.00

Average Price Target$477.38

Lowest Price Target$406.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stephen Baxter

Wells Fargo

$473→$492

Buy

24.19%

Upside

Assigned

10/27/26

Stephen Baxter Boosts Elevance Health Price Target to $492 on Strong Core Earnings and Favorable Medicare Outlook

Ann Hynes

Mizuho Securities

$470→$490

Buy

23.68%

Upside

Reiterated

10/23/26

Elevance Health price target raised to $490 from $470 at MizuhoElevance Health price target raised to $490 from $470 at Mizuho

Ryan Langston

TD Cowen

$465→$495

Buy

24.95%

Upside

Reiterated

10/23/26

TD Cowen Reaffirms Their Buy Rating on Elevance Health (ELV)

David S Macdonald

Truist Financial

$475→$500

Buy

26.21%

Upside

Reiterated

10/22/26

Elevance Health price target raised to $500 from $475 at TruistElevance Health price target raised to $500 from $475 at Truist

Erin Wright

Morgan Stanley

$404→$449

Hold

13.34%

Upside

Reiterated

10/22/26

Elevance Health price target raised to $449 from $404 at Morgan StanleyElevance Health price target raised to $449 from $404 at Morgan Stanley

A.J. Rice

UBS

$460→$523

Buy

32.01%

Upside

Assigned

10/22/26

Elevance Health price target raised to $523 from $460 at UBSElevance Health price target raised to $523 from $460 at UBS

Scott Fidel

Goldman Sachs

$395→$451

Hold

13.84%

Upside

Reiterated

10/22/26

Elevance Health price target raised to $451 from $395 at Goldman SachsElevance Health price target raised to $451 from $395 at Goldman Sachs

Kevin Fischbeck

Bank of America Securities

$500

Buy

26.21%

Upside

Assigned

10/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB), Elevance Health (NYSE: ELV) and Myriad Genetics (NASDAQ: MYGN)

Michael Ha

Robert W. Baird

$393→$406

Hold

2.48%

Upside

Reiterated

10/22/26

Elevance Health price target raised to $406 from $393 at BairdElevance Health price target raised to $406 from $393 at Baird

Andrew Mok CFA

Barclays

$469→$472

Buy

19.14%

Upside

Reiterated

10/22/26

Barclays Keeps Their Buy Rating on Elevance Health (ELV)

Ben Hendrix

RBC Capital

$424→$455

Hold

14.85%

Upside

Reiterated

10/21/26

Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), Elevance Health (NYSE: ELV) and Abbott Laboratories (NYSE: ABT)

Jason Cassorla

Guggenheim

$460→$485

Buy

22.42%

Upside

Reiterated

10/21/26

Elevance Health price target raised to $485 from $460 at GuggenheimElevance Health price target raised to $485 from $460 at Guggenheim

Lance Wilkes

Bernstein

$488

Buy

23.18%

Upside

Reiterated

10/05/26

Bernstein Reaffirms Their Buy Rating on Elevance Health (ELV)

David Toung

Argus Research

―

Hold

―

Reiterated

08/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Shenzhen Edge Medical Co., Ltd. Class H (HKEX: HK:2675), Elevance Health (NYSE: ELV) and 4DMedical Ltd (ASX: AU:4DX)

Whit Mayo

Leerink Partners

$364→$395

Hold

-0.30%

Downside

Reiterated

07/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stephen Baxter

Wells Fargo

$473→$492

Buy

24.19%

Upside

Assigned

10/27/26

Stephen Baxter Boosts Elevance Health Price Target to $492 on Strong Core Earnings and Favorable Medicare Outlook

Ann Hynes

Mizuho Securities

$470→$490

Buy

23.68%

Upside

Reiterated

10/23/26

Elevance Health price target raised to $490 from $470 at MizuhoElevance Health price target raised to $490 from $470 at Mizuho

Ryan Langston

TD Cowen

$465→$495

Buy

24.95%

Upside

Reiterated

10/23/26

TD Cowen Reaffirms Their Buy Rating on Elevance Health (ELV)

David S Macdonald

Truist Financial

$475→$500

Buy

26.21%

Upside

Reiterated

10/22/26

Elevance Health price target raised to $500 from $475 at TruistElevance Health price target raised to $500 from $475 at Truist

Erin Wright

Morgan Stanley

$404→$449

Hold

13.34%

Upside

Reiterated

10/22/26

Elevance Health price target raised to $449 from $404 at Morgan StanleyElevance Health price target raised to $449 from $404 at Morgan Stanley

A.J. Rice

UBS

$460→$523

Buy

32.01%

Upside

Assigned

10/22/26

Elevance Health price target raised to $523 from $460 at UBSElevance Health price target raised to $523 from $460 at UBS

Scott Fidel

Goldman Sachs

$395→$451

Hold

13.84%

Upside

Reiterated

10/22/26

Elevance Health price target raised to $451 from $395 at Goldman SachsElevance Health price target raised to $451 from $395 at Goldman Sachs

Kevin Fischbeck

Bank of America Securities

$500

Buy

26.21%

Upside

Assigned

10/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB), Elevance Health (NYSE: ELV) and Myriad Genetics (NASDAQ: MYGN)

Michael Ha

Robert W. Baird

$393→$406

Hold

2.48%

Upside

Reiterated

10/22/26

Elevance Health price target raised to $406 from $393 at BairdElevance Health price target raised to $406 from $393 at Baird

Andrew Mok CFA

Barclays

$469→$472

Buy

19.14%

Upside

Reiterated

10/22/26

Barclays Keeps Their Buy Rating on Elevance Health (ELV)

Ben Hendrix

RBC Capital

$424→$455

Hold

14.85%

Upside

Reiterated

10/21/26

Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), Elevance Health (NYSE: ELV) and Abbott Laboratories (NYSE: ABT)

Jason Cassorla

Guggenheim

$460→$485

Buy

22.42%

Upside

Reiterated

10/21/26

Elevance Health price target raised to $485 from $460 at GuggenheimElevance Health price target raised to $485 from $460 at Guggenheim

Lance Wilkes

Bernstein

$488

Buy

23.18%

Upside

Reiterated

10/05/26

Bernstein Reaffirms Their Buy Rating on Elevance Health (ELV)

David Toung

Argus Research

―

Hold

―

Reiterated

08/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Shenzhen Edge Medical Co., Ltd. Class H (HKEX: HK:2675), Elevance Health (NYSE: ELV) and 4DMedical Ltd (ASX: AU:4DX)

Whit Mayo

Leerink Partners

$364→$395

Hold

-0.30%

Downside

Reiterated

07/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

REPLReplimune Group

VSTMVerastem

OVIDOvid Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months

Andrew Mok CFABarclays

Success Rate

13/19 ratings generated profit

Average Return

+1.35%

Copying Andrew Mok CFA's trades and holding each position for 3 Months would result in 68.42% of your transactions generating a profit, with an average return of +1.35% per trade.

1 Year

George HillDeutsche Bank

Success Rate

14/18 ratings generated profit

Average Return

+16.06%

Copying George Hill's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +16.06% per trade.

2 Years

A.J. RiceUBS

Success Rate

28/31 ratings generated profit

Average Return

+37.96%

Copying A.J. Rice's trades and holding each position for 2 Years would result in 90.32% of your transactions generating a profit, with an average return of +37.96% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HG8 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0HG8 has received 20 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 0HG8 average Analyst price target in the past 3 months is 477.38.

Each month's total comprises the sum of three months' worth of ratings.

0HG8 Financial Forecast

0HG8 Earnings Forecast

Next quarter’s earnings estimate for 0HG8 is $2.08 with a range of $1.64 to $3.22. The previous quarter’s EPS was $6.99. 0HG8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HG8 has Performed in-line its overall industry.

0HG8 Sales Forecast

Next quarter’s sales forecast for 0HG8 is $49.38B with a range of $47.02B to $52.00B. The previous quarter’s sales results were $51.43B. 0HG8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HG8 has Performed in-line its overall industry.

0HG8 Stock Forecast FAQ

What is GB:0HG8’s average 12-month price target, according to analysts?

Based on analyst ratings, Elevance Health’s 12-month average price target is 477.38.

What is GB:0HG8’s upside potential, based on the analysts’ average price target?

Elevance Health has 20.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Elevance Health a Buy, Sell or Hold?

Elevance Health has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 5 hold ratings and 0 sell ratings.

What is Elevance Health’s share price target?

The average share price target for Elevance Health is 477.38. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $523.00 ,and the lowest forecast is $406.00. The average share price target represents 20.50% Increase from the current price of $396.17.

What do analysts say about Elevance Health?

Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Elevance Health?

To buy shares of GB:0HG8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Elevance Health (0HG8) Share Forecast & Price Target

0HG8 Analyst Ratings

0HG8 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Elevance Health

0HG8 Analyst Recommendation Trends

0HG8 Financial Forecast

0HG8 Earnings Forecast

0HG8 Sales Forecast

0HG8 Stock Forecast FAQ

Detailed List of Analyst Forecasts